PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-16.72%
Cash & equivalents declining -16.72% while AXSM's grows 22.94%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Below half of AXSM's 22.94%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-19.08%
Below half of AXSM's 21.58%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-14.24%
≥ 1.5x AXSM's -7.16%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.11%
≥ 1.5x AXSM's -0.35%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Below half of AXSM's 21.46%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-4.20%
Less than half of AXSM's 16.16%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.87%
Less than half of AXSM's -100.00%. David Dodd sees fewer expansions in other current obligations.
18.79%
1.1-1.25x AXSM's 16.53%. Bill Ackman questions if the firm is taking on more near-term obligations than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.79%
Above 1.5x AXSM's 2.94%. Michael Burry sees a potential leverage warning sign.
2.42%
Less than half of AXSM's 22.86%. David Dodd sees fewer share issuances vs. competitor.
-5.90%
Below half AXSM's -16.78%. Michael Burry suspects major net losses or high dividends vs. competitor.
-12.27%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-28.51%
Below half AXSM's 161.46%. Michael Burry sees potential underperformance in building shareholder capital.
-19.02%
Below half AXSM's 249.71%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.72%
Less than half of AXSM's -30.83%. David Dodd sees better deleveraging or stronger cash buildup than competitor.